CytomX Therapeutics, Inc.
CTMX
$2.03
$0.031.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -154.00K | 23.53M | 18.88M | 5.74M | -6.53M |
| Total Depreciation and Amortization | 347.00K | 385.00K | 413.00K | 429.00K | 459.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.14M | 2.64M | 2.26M | 1.81M | 1.45M |
| Change in Net Operating Assets | -18.09M | -47.59M | -41.46M | -28.70M | -14.93M |
| Cash from Operations | -15.75M | -21.04M | -19.91M | -20.73M | -19.55M |
| Capital Expenditure | -27.00K | -119.00K | -80.00K | -19.00K | -96.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -76.33M | 30.72M | 15.22M | 18.19M | 21.61M |
| Cash from Investing | -76.36M | 30.60M | 15.14M | 18.17M | 21.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 93.55M | -- | 2.25M | 0.00 | 5.10M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 93.55M | -- | 2.25M | 0.00 | 5.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.44M | 9.55M | -2.52M | -2.56M | 7.06M |